API

Active Pharmaceutical Ingredients (API), popularly speaking, are the raw materials of medicines, only pharmaceutical raw materials are processed into pharmaceutical preparations , can they become medicines available for clinical use, so drugs we usually eat are the finished drugs through processing. Active Pharmaceutical Ingredients based on its sources can be divided into two major categories ,including chemical synthetic drugs and natural chemical drugs. Chemical synthetic drugs can be divided into organic synthetic drugs and inorganic synthetic drugs. Inorganic synthetic drugs are inorganic compounds ( very few is element), such as aluminum hydroxide, magnesium trisilicate which are used for the treatment of gastric and duodenal ulcers ; organic synthetic drugs are mainly composed of drugs made by basic organic chemical raw materials, through a series of organic chemical reactions (such as aspirin, chloramphenicol, caffeine, etc.). Natural chemical drugs ,based on its sources,can be divided into two categories including biochemical drugs and plant chemical drugs. Antibiotics are generally made by the microbial fermentation, which belongs to the biochemistry category. A variety of semi-synthetic antibiotics occurs in recent years,which are biosynthesis and chemical synthesis combining products.Among active Pharmaceutical Ingredients, the organic synthetic drugs varieties, yields and values have the largest proportion,which are the main pillars of the chemical and pharmaceutical industries. The quality of active Pharmaceutical Ingredients decides whether the formulation is good or bad , so its quality standards are very strict ,countries in the world have developed national pharmacopoeia standards and strict quality control methods for its widely used active Pharmaceutical ingredients.

Afoxolaner: An Effective Insecticide and Acaricide for Flea and Tick Infestations in Dogs

Afoxolaner is an isoxazoline insecticide used for treating flea and tick infestations in dogs. It inhibits chloride ion channels, providing efficient killing upon contact or ingestion.

Feb 5,2024  API

How to synthesize Trastuzumab Deruxtecan?

Preparation of the final drug product, trastuzumab deruxtecan, necessitated conjugation of deruxtecan to the anti-HER2 monoclonal antibody trastuzumab, generating the ADC with a loading of approximat

Feb 4,2024  API

The introduction of Trastuzumab Deruxtecan

Trastuzumab deruxtecan, a HER2-directed antibody and DNA topoisomerase I inhibitor conjugate, is being developed for the treatment of HER2-expressing solid tumors.

Feb 4,2024  API

How to synthesize Elexacaftor?

Ivacaftor is a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator, while elexacaftor and tezacaftor are CFTR correctors.

Feb 4,2024  API

Advancements in Lithium Borohydride for Enhanced Hydrogen Storage

Lithium Borohydride is a white solid with multiple crystal forms, soluble in polar solvents. Research aims to enhance its hydrogen storage properties for practical applications.

Feb 4,2024  API

Milbemycin Oxime: A Broad-Spectrum Antiparasitic Drug in Veterinary Medicine

Milbemycin oxime is a broad-spectrum antiparasitic drug used to prevent heartworm disease and treat intestinal parasites in dogs with monthly administration and consultation with a veterinarian.

Feb 4,2024  API

2-Phenylimidazole: A Versatile Compound with Applications in Dye Synthesis and p-Nitrophenol Removal

2-Phenylimidazole is a valuable compound with applications in coordination chemistry, pharmaceutical synthesis, azo dye production, and p-nitrophenol removal from wastewater.

Feb 4,2024  API

Chloroquine Diphosphate: Adverse Effects and Degradation Pathways

Chloroquine diphosphate has adverse effects and is susceptible to degradation. Proper storage and avoidance of interactions are crucial.

Feb 4,2024  API

How to synthesis Relugolix?

Relugolix was recently approved for marketing in Japan as a treatment for symptoms associated with uterine fibroids.

Feb 2,2024  API

Dabigatran Etexilate: A Potent Thrombin Inhibitor for Stroke Prevention in Non-Valvular Atrial Fibrillation

Dabigatran Etexilate, a prodrug converted to dabigatran, selectively inhibits clot formation. RE-LY trial showed noninferiority/superiority to warfarin in preventing stroke/embolism.

Feb 2,2024  API
Prev12345678910...Next>  Go to Page